Sensorion announces oral presentation at the European Histamine Research Society. pdfRead

Sensorion announces the positive Data Safety Monitoring Board (DSMB) review and continuation of the phase 2 clinical trial for SENS-111 in acute unilateral vestibulopathy (AUV). 86 patients enrolled in SENS-111 clinical trial. pdfRead

Sensorion’s 2018 financial report is now available. pdfRead

Sensorion reports its 2018 annual results. 75% of patients enrolled in the Sens-111 clinical trial. pdfRead

Sensorion strengthens its financial structure by issuing a €4.7 million nominal bond issue subscribed by new European investors and management. Bpifrance has selected Sensorion for its program "Hub Health Tech". pdfRead


20191220 pipeline


Patient center

Corporate presentation